Derlin, T.; Bogdanova, N.; Ohlendorf, F.; Ramachandran, D.; Werner, R.A.; Ross, T.L.; Christiansen, H.; Bengel, F.M.; Henkenberens, C.
Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Cancers 2021, 13, 1516.
https://doi.org/10.3390/cancers13071516
AMA Style
Derlin T, Bogdanova N, Ohlendorf F, Ramachandran D, Werner RA, Ross TL, Christiansen H, Bengel FM, Henkenberens C.
Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Cancers. 2021; 13(7):1516.
https://doi.org/10.3390/cancers13071516
Chicago/Turabian Style
Derlin, Thorsten, Natalia Bogdanova, Fiona Ohlendorf, Dhanya Ramachandran, Rudolf A. Werner, Tobias L. Ross, Hans Christiansen, Frank M. Bengel, and Christoph Henkenberens.
2021. "Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors" Cancers 13, no. 7: 1516.
https://doi.org/10.3390/cancers13071516
APA Style
Derlin, T., Bogdanova, N., Ohlendorf, F., Ramachandran, D., Werner, R. A., Ross, T. L., Christiansen, H., Bengel, F. M., & Henkenberens, C.
(2021). Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 13(7), 1516.
https://doi.org/10.3390/cancers13071516